EUCTR2016-004586-67-NL进行中（未招募）1 期
BYLieve: A phase II, multicenter, open-label, three-cohort, noncomparative study to assess the efficacy and safety of alpelisib plus fulvestrant or letrozole in patients with PIK3CA mutant, hormone receptor (HR) positive, HER2-negative advanced breast cancer (aBC), who have progressed on or after prior treatments - BYLieve
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 340
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Patient is male or female 18 years or older
- •- Patient is identified PIK3CA mutant status
- •- Patient has confirmed HER2-negative advanced breast cancer (aBC)
- •-Patient must be diagnosed with aBC with documented progression on or after prior treatment
- •- Patient has histological and/or cytological confirmed ER+ and/or PgR+ aBC
- •- Patient has either measurable disease per RECIST v1.1 or at least one predominantly lytic bone lesion must be present
- •- ECOG function of greater or equal to 2
- •- Patient has adequate bone marrow function
- •- Patient has adequate liver and renal function
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 60
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 280
排除标准
- •- patient has received prior treatment with any PI3K inhibitors
- •- patient with clinically manifest diabetes mellitus, or documented steroid induced diabetes mellitus
- •-Patient has a concurrent malignancy or malignancy within 3 years of study screening period, with the exception of adequately treated, basal
- •or squamous cell carcinoma, non-melanoma skin cancer or curatively resected cervical cancer
- •-Patient has received radiotherapy = 4 weeks or limited field radiation for palliation = 2 weeks prior to enrollment, and who has not recovered to grade 1 or better from related side effects of such therapy
- •-History of acute pancreatitis within 1 year of screening or past medical history of pancreatitis
- •-Patients with central nervous system (CNS) involvement unless they meet ALL of the following criteria:
- •At least 4 weeks from prior therapy completion (including radiation and/or surgery) to starting the study treatment
- •Clinically stable CNS tumor at the time of screening untreated or without evidence of progressions for at least 4 weeks after treatment as determined by clinical examination and brain imaging (MRI or CT) during screening period and stable low dose of steroids for 2 weeks prior to
- •initiating study treatment
- •-Patient with severe liver impairment (Child Pugh score B/C)
- •-Patient has impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of the study drugs based on
- •investigator discretion
- •-Patient has documented pneumonitis/interstitial lung disease which is active and requiring treatment
- •-Patient has a history of severe cutaneous reactions like Stevens Johnson-Syndrome (SJS), Erythema Multiforme (EM), or Toxic Epidermal Necrolysis (TEN) or Drug Reaction with Eosinphilia and Systemic Symptoms (DRESS)
- •-Subjects with unresolved osteonecrosis of the jaw